Polygenic risk score portability for common diseases across genetically diverse populations.

IF 3.8 3区 医学 Q2 GENETICS & HEREDITY
Sonia Moreno-Grau, Manvi Vernekar, Arturo Lopez-Pineda, Daniel Mas-Montserrat, Míriam Barrabés, Consuelo D Quinto-Cortés, Babak Moatamed, Ming Ta Michael Lee, Zhenning Yu, Kensuke Numakura, Yuta Matsuda, Jeffrey D Wall, Alexander G Ioannidis, Nicholas Katsanis, Tomohiro Takano, Carlos D Bustamante
{"title":"Polygenic risk score portability for common diseases across genetically diverse populations.","authors":"Sonia Moreno-Grau, Manvi Vernekar, Arturo Lopez-Pineda, Daniel Mas-Montserrat, Míriam Barrabés, Consuelo D Quinto-Cortés, Babak Moatamed, Ming Ta Michael Lee, Zhenning Yu, Kensuke Numakura, Yuta Matsuda, Jeffrey D Wall, Alexander G Ioannidis, Nicholas Katsanis, Tomohiro Takano, Carlos D Bustamante","doi":"10.1186/s40246-024-00664-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Polygenic risk scores (PRS) derived from European individuals have reduced portability across global populations, limiting their clinical implementation at worldwide scale. Here, we investigate the performance of a wide range of PRS models across four ancestry groups (Africans, Europeans, East Asians, and South Asians) for 14 conditions of high-medical interest.</p><p><strong>Methods: </strong>To select the best-performing model per trait, we first compared PRS performances for publicly available scores, and constructed new models using different methods (LDpred2, PRS-CSx and SNPnet). We used 285 K European individuals from the UK Biobank (UKBB) for training and 18 K, including diverse ancestries, for testing. We then evaluated PRS portability for the best models in Europeans and compared their accuracies with respect to the best PRS per ancestry. Finally, we validated the selected PRS models using an independent set of 8,417 individuals from Biobank of the Americas-Genomelink (BbofA-GL); and performed a PRS-Phewas.</p><p><strong>Results: </strong>We confirmed a decay in PRS performances relative to Europeans when the evaluation was conducted using the best-PRS model for Europeans (51.3% for South Asians, 46.6% for East Asians and 39.4% for Africans). We observed an improvement in the PRS performances when specifically selecting ancestry specific PRS models (phenotype variance increase: 1.62 for Africans, 1.40 for South Asians and 0.96 for East Asians). Additionally, when we selected the optimal model conditional on ancestry for CAD, HDL-C and LDL-C, hypertension, hypothyroidism and T2D, PRS performance for studied populations was more comparable to what was observed in Europeans. Finally, we were able to independently validate tested models for Europeans, and conducted a PRS-Phewas, identifying cross-trait interplay between cardiometabolic conditions, and between immune-mediated components.</p><p><strong>Conclusion: </strong>Our work comprehensively evaluated PRS accuracy across a wide range of phenotypes, reducing the uncertainty with respect to which PRS model to choose and in which ancestry group. This evaluation has let us identify specific conditions where implementing risk-prioritization strategies could have practical utility across diverse ancestral groups, contributing to democratizing the implementation of PRS.</p>","PeriodicalId":13183,"journal":{"name":"Human Genomics","volume":"18 1","pages":"93"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367857/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40246-024-00664-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Polygenic risk scores (PRS) derived from European individuals have reduced portability across global populations, limiting their clinical implementation at worldwide scale. Here, we investigate the performance of a wide range of PRS models across four ancestry groups (Africans, Europeans, East Asians, and South Asians) for 14 conditions of high-medical interest.

Methods: To select the best-performing model per trait, we first compared PRS performances for publicly available scores, and constructed new models using different methods (LDpred2, PRS-CSx and SNPnet). We used 285 K European individuals from the UK Biobank (UKBB) for training and 18 K, including diverse ancestries, for testing. We then evaluated PRS portability for the best models in Europeans and compared their accuracies with respect to the best PRS per ancestry. Finally, we validated the selected PRS models using an independent set of 8,417 individuals from Biobank of the Americas-Genomelink (BbofA-GL); and performed a PRS-Phewas.

Results: We confirmed a decay in PRS performances relative to Europeans when the evaluation was conducted using the best-PRS model for Europeans (51.3% for South Asians, 46.6% for East Asians and 39.4% for Africans). We observed an improvement in the PRS performances when specifically selecting ancestry specific PRS models (phenotype variance increase: 1.62 for Africans, 1.40 for South Asians and 0.96 for East Asians). Additionally, when we selected the optimal model conditional on ancestry for CAD, HDL-C and LDL-C, hypertension, hypothyroidism and T2D, PRS performance for studied populations was more comparable to what was observed in Europeans. Finally, we were able to independently validate tested models for Europeans, and conducted a PRS-Phewas, identifying cross-trait interplay between cardiometabolic conditions, and between immune-mediated components.

Conclusion: Our work comprehensively evaluated PRS accuracy across a wide range of phenotypes, reducing the uncertainty with respect to which PRS model to choose and in which ancestry group. This evaluation has let us identify specific conditions where implementing risk-prioritization strategies could have practical utility across diverse ancestral groups, contributing to democratizing the implementation of PRS.

不同基因人群常见疾病的多基因风险评分可移植性。
背景:源自欧洲人的多基因风险评分(PRS)在全球人群中的可移植性较差,限制了其在全球范围内的临床应用。在此,我们研究了四个祖先群体(非洲人、欧洲人、东亚人和南亚人)的各种多基因风险评分模型在 14 种具有高度医学意义的疾病中的表现:为了选出每个性状中表现最好的模型,我们首先比较了公开分数的 PRS 表现,并使用不同的方法(LDpred2、PRS-CSx 和 SNPnet)构建了新模型。我们使用英国生物库 (UKBB) 中的 285 K 个欧洲人进行训练,并使用 18 K 个欧洲人(包括不同的祖先)进行测试。然后,我们评估了欧洲人最佳模型的 PRS 可移植性,并将其准确性与每个祖先的最佳 PRS 进行了比较。最后,我们使用来自美洲基因组链接生物库(BbofA-GL)的 8417 个独立个体验证了所选的 PRS 模型,并进行了 PRS-Phewas 分析:当使用欧洲人的最佳 PRS 模型进行评估时,我们证实相对于欧洲人的 PRS 性能有所下降(南亚人 51.3%,东亚人 46.6%,非洲人 39.4%)。我们观察到,在特别选择特定祖先的 PRS 模型时,PRS 的性能有所提高(表型方差增加:非洲人增加 1.62,南亚人增加 1.40,东亚人增加 0.96)。此外,当我们为 CAD、HDL-C 和 LDL-C、高血压、甲状腺机能减退和 T2D 选择了以血统为条件的最佳模型时,研究人群的 PRS 表现与在欧洲人中观察到的表现更为相似。最后,我们对欧洲人的测试模型进行了独立验证,并进行了 PRS-Phewas,确定了心血管代谢条件之间以及免疫介导成分之间的跨性状相互作用:我们的工作全面评估了各种表型的 PRS 准确性,减少了选择哪种 PRS 模型和哪个祖先群体的不确定性。这项评估让我们确定了在哪些特定条件下实施风险优先策略对不同的祖先群体具有实际效用,从而为 PRS 的民主化实施做出了贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Genomics
Human Genomics GENETICS & HEREDITY-
CiteScore
6.00
自引率
2.20%
发文量
55
审稿时长
11 weeks
期刊介绍: Human Genomics is a peer-reviewed, open access, online journal that focuses on the application of genomic analysis in all aspects of human health and disease, as well as genomic analysis of drug efficacy and safety, and comparative genomics. Topics covered by the journal include, but are not limited to: pharmacogenomics, genome-wide association studies, genome-wide sequencing, exome sequencing, next-generation deep-sequencing, functional genomics, epigenomics, translational genomics, expression profiling, proteomics, bioinformatics, animal models, statistical genetics, genetic epidemiology, human population genetics and comparative genomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信